Clinical and Biochemical Phenotypes of Adults with Monoallelic and Biallelic CYP24A1 Mutations: Evidence of Gene Dose Effect

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2016 May 1

PMID 27129455

Citations 17

Authors

D T OKeeffe

P J Tebben

R Kumar

R J Singh

Y Wu

R A Wermers

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Mutations of the CYP24A1 gene can result in hypercalcemia, hyerpercalciuria, and nephrolithiasis, but disease severity is variable. Clinical and biochemical phenotypes were correlated with gene sequence information in a family with two CYP24A1 mutations. A gene dose effect was apparent with monoallelic mutations demonstrating milder disease manifestations than biallelic mutations.

Introduction: The objective was to examine the spectrum of clinical and biochemical phenotypes in a family with monoallelic and biallelic mutations of CYP24A1 after identification of the proband with two mutations of the CYP24A1 gene: (A) p.R396W and (B) E143del-Het.

Methods: Clinical and biochemical phenotypes were correlated with CYP24A1 sequence information in the proband and four siblings, a daughter, and two nieces of the proband. The subjects' medical histories were evaluated, and measurement of serum minerals, vitamin D metabolites, PTH, bone turnover markers, and urinary calcium and sequencing of the CYP24A1 gene were performed.

Results: The proband had nephrolithiasis, osteopenia, hypercalcemia, hypercalciuria, elevated serum 1,25(OH)2D, undetectable 24,25(OH)2D, and inappropriately low PTH concentrations. Two subjects with biallelic (A/B) mutations had nephrolithiasis, marked hypercalciuria (583 ± 127 mg/24 h, mean ± SD), compared with five subjects with monoallelic mutations (A or B) with a urine calcium of 265 ± 85 mg/24 h. Two subjects with monoallelic mutations had nephrolithiasis and one had non-PTH dependent hypercalcemia. Five subjects had high 1,25(OH)2D measurements, including three with monoallelic mutations. The 25OHD/24,25(OH)2D ratio, in subjects with biallelic mutations was 291 versus 19.8 in the subjects with monoallelic mutations.

Conclusions: In this family, adults with CYP24A1 mutations a gene dose effect is apparent: subjects with biallelic, compound heterozygous mutations (A/B) have a more severe clinical and biochemical phenotype, whereas, subjects with monoallelic mutations demonstrate milder disease manifestations which are not easily characterized through biochemical assessment.

Citing Articles

The Vitamin D Metabolite Diagnostic Ratio Associates With Phenotypic Traits of Idiopathic Hypercalciuria.

Dhayat N, Mattmann C, Seeger H, Ritter A, Ernandez T, Stoermann-Chopard C Kidney Int Rep. 2024; 9(4):1072-1082.

PMID: 38765596 PMC: 11101794. DOI: 10.1016/j.ekir.2024.01.004.

Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D.

Mohan S, Sheehan M, Tebben P, Wermers R JCEM Case Rep. 2024; 2(3):luae022.

PMID: 38476635 PMC: 10928506. DOI: 10.1210/jcemcr/luae022.

Hypervitaminosis D Secondary to a Loss-of-Function Mutation: An Unusual Cause of Hypercalcemia in Two Siblings.

Collins L, Boehm E, Luxford C, Clifton-Bligh R, Grill V JBMR Plus. 2023; 7(9):e10788.

PMID: 37701149 PMC: 10494500. DOI: 10.1002/jbm4.10788.

CYP24A1 and CYP3A4 Levels, Renal, Hepatic Changes, and Incidence of Oxidative Stress in Tramadol-Alcohol Concomitant Misuse.

Dic-Ijiewere E, Osadolor H Cureus. 2023; 15(3):e36877.

PMID: 37123794 PMC: 10147408. DOI: 10.7759/cureus.36877.

Case report: Two heterozygous pathogenic variants of CYP24A1: A novel cause of hypercalcemia and nephrocalcinosis in adulthood.

Brunerova L, Remes O, Zoubkova V, Votypka P Front Med (Lausanne). 2023; 9:1020096.

PMID: 36703897 PMC: 9871448. DOI: 10.3389/fmed.2022.1020096.

References

Kumar R . The metabolism of 1,25-dihydroxyvitamin D3. Endocr Rev. 1980; 1(3):258-67. DOI: 10.1210/edrv-1-3-258. View

Tebben P, Milliner D, Horst R, Harris P, Singh R, Wu Y . Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab. 2012; 97(3):E423-7. PMC: 3319216. DOI: 10.1210/jc.2011-1935. View

Dauber A, Nguyen T, Sochett E, Cole D, Horst R, Abrams S . Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab. 2011; 97(2):E268-74. PMC: 3275367. DOI: 10.1210/jc.2011-1972. View

Plum L, Deluca H . Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010; 9(12):941-55. DOI: 10.1038/nrd3318. View

Dowen F, Sayers J, Hynes A, Sayer J . CYP24A1 mutation leading to nephrocalcinosis. Kidney Int. 2014; 85(6):1475. DOI: 10.1038/ki.2013.416. View

Cools M, Goemaere S, Baetens D, Raes A, Desloovere A, Kaufman J . Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study. Bone. 2015; 81:89-96. DOI: 10.1016/j.bone.2015.06.018. View

Molin A, Baudoin R, Kaufmann M, Souberbielle J, RYCKEWAERT A, Vantyghem M . CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait. J Clin Endocrinol Metab. 2015; 100(10):E1343-52. DOI: 10.1210/jc.2014-4387. View

Kumar R . Metabolism of 1,25-dihydroxyvitamin D3. Physiol Rev. 1984; 64(2):478-504. DOI: 10.1152/physrev.1984.64.2.478. View

Jones G, Prosser D, Kaufmann M . 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2011; 523(1):9-18. DOI: 10.1016/j.abb.2011.11.003. View

10.

Nesterova G, Malicdan M, Yasuda K, Sakaki T, Vilboux T, Ciccone C . 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis. Clin J Am Soc Nephrol. 2013; 8(4):649-57. PMC: 3613951. DOI: 10.2215/CJN.05360512. View

11.

Ketha H, Singh R, Grebe S, Bergstralh E, Rule A, Lieske J . Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. PLoS One. 2015; 10(9):e0137350. PMC: 4558059. DOI: 10.1371/journal.pone.0137350. View

12.

Ketha H, Kumar R, Singh R . LC-MS/MS for Identifying Patients with CYP24A1 Mutations. Clin Chem. 2015; 62(1):236-42. DOI: 10.1373/clinchem.2015.244459. View

13.

Schlingmann K, Kaufmann M, Weber S, Irwin A, Goos C, John U . Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011; 365(5):410-21. DOI: 10.1056/NEJMoa1103864. View

14.

Jacobs T, Kaufman M, Jones G, Kumar R, Schlingmann K, Shapses S . A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab. 2014; 99(3):708-12. PMC: 3942238. DOI: 10.1210/jc.2013-3802. View

15.

Fraser D . The relation between infantile hypercalcemia and vitamin D--public health implications in North America. Pediatrics. 1967; 40(6):1050-61. View

16.

Streeten E, Zarbalian K, Damcott C . CYP24A1 mutations in idiopathic infantile hypercalcemia. N Engl J Med. 2011; 365(18):1741-2. DOI: 10.1056/NEJMc1110226. View

17.

Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman E . Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol. 2013; 190(2):552-7. DOI: 10.1016/j.juro.2013.02.3188. View

18.

Masuda S, Byford V, Arabian A, Sakai Y, Demay M, St-Arnaud R . Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 2004; 146(2):825-34. DOI: 10.1210/en.2004-1116. View